International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI)
Predicts overall and progression-free survival in DLBCL based on risk factors.
INSTRUCTIONS
Note: IPI results are included for historical comparisons only. Use in CD20+ DLBCL patients. Do not use in patients with HIV, secondary malignancies, low grade lymphoproliferative disorders, or comorbidities precluding curative therapy attempt.
When to Use
Pearls/Pitfalls
Why Use
≤60 years
0>60 years
+1No
0Yes
+1No
0Yes
+1No
0Yes
+1No
0Yes
+1Result:
Please fill out required fields.